CONBA Pharmaceutical Chair Resigns

MT NewswiresDec 8 17:26

Express News | Conba: Chairman Jiang Yi has stepped down.

BreakingsDec 5 16:55

Targeting fields such as cell and gene therapy, and brain-computer interfaces! Shanghai's new pharmaceutical policies unleash multiple benefits, with innovative drugs and medical devices becoming the focal point.

In recent days, multiple brokerage research institutions have issued research reports expressing optimism about innovative medical devices and the innovative pharmaceuticals industry chain.

China SecuritiesNov 24 21:28

Research Report Insights | Zhejiang Securities: Reiterates 'Buy' Rating for Conba, Brand Products Expected to Achieve Steady Growth

Gelonghui, November 21 | A research report by Zheshang Securities pointed out that Kangenbei's year-on-year revenue growth rates for Q1-Q3 of 2025 were -7.64%, +3.04%, and +10.42%, respectively, showing continuous quarter-on-quarter improvement. The main factors dragging down the first-half performance were respiratory drugs such as 'Jindi' brand Compound Houttuynia Cordata Solution, which were affected by a high base during the flu season in the first half of 2024. Meanwhile, gastrointestinal and metabolic drugs such as Changyaning achieved a year-on-year increase of 16.51% in the first half of 2025. Looking ahead to Q4 2025 and 2026, it is expected that with the normalization of flu-related data and the deepening of the mixed-ownership reform process, the brand-focused strategy will stabilize.

Gelonghui FinanceNov 21 14:51 · Ratings

Conba (600572): Inflection point in performance achieved; a strong start to the '15th Five-Year Plan' anticipated.

Key investment points: Quarterly performance growth is recovering sequentially, and branded products are expected to achieve steady growth. The company's year-on-year revenue growth rates for Q1-Q3 2025 were -7.64%, +3.04%, and +10.42%, respectively, showing continuous improvement on a quarter-over-quarter basis; in particular, the

Zhejiang SecuritiesNov 21 07:27

Comment on Conba (600572) Q3 2025 Earnings Report: Continued Focus on R&D, Positive Outlook for Long-Term Value

Key Highlights: The company achieved revenue of RMB 4.98 billion in the first three quarters of the year (up 1.3% YoY), with net profit attributable to shareholders amounting to RMB 580 million (up 12.6% YoY), and non-recurring net profit attributable to shareholders at RMB 430 million (up 1.6% YoY).

Huachuang SecuritiesNov 20 07:57